We also saw an expansion of MEDIDATA with some key players such as Regeneron and new customers ... And it’s an interesting case because it’s a new logo for us, right? It’s – we had some ...

After issues at a third-party manufacturer caused the FDA to reject Regeneron's multiple myeloma bispecific antibody ...

Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Regeneron (REGN) announced an expansion of its manufacturing capacity through a new agreement with Fujifilm Diosynth Biotechnologies to ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Regeneron signs $3 billion deal with FUJIFILM to expand biologics manufacturing in North Carolina, boosting U.S. capacity and ...

Fujifilm will produce drugs for Regeneron, maker of the $14 billion a year inflammation treatment Dupixent, at its facility in Holly Springs, North Carolina. The site is slated to begin operations ...

(Reuters) -Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth, potentially doubling its U.S. manufacturing ...

A significant chunk of Regeneron’s revenues comes from the sale of its lead drug, Eylea, which is approved for various ophthalmology indications (neovascular age-related macular degeneration ...